MedDataX Logo

Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension

NCT ID: NCT00281580

Last Updated: 2014-03-27

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1461 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To demonstrate that Micardis and Norvasc when used together are more effective at lowering blood pre ssure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension

NCT00281593

Hypertension
COMPLETED PHASE3

Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension

NCT00558428

Hypertension
COMPLETED PHASE3

Telmisartan and Amlodipine Versus Monocomponent Tablets

NCT01278797

Hypertension
COMPLETED PHASE1

Pharmacokinetics of Telmisartan Alone and in Combination With Amlodipine in Healthy Volunteers

NCT02259816

Healthy
COMPLETED PHASE1

Telmisartan Versus Amlodipine in Patients With Mild-to-Moderate Hypertension

NCT02177409

Hypertension
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Placebo once daily for eight weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo to Telmisartan and Amlodipine once daily for eight weeks

Telmisartan 20 mg

Telmisartan 20 mg once daily for eight weeks

Group Type EXPERIMENTAL

Telmisartan 20 mg

Intervention Type DRUG

Telmisartan 20 mg once daily for eight weeks

Telmisartan 40 mg

Telmisartan 40 mg once daily for eight weeks

Group Type EXPERIMENTAL

Telmisartan 40 mg

Intervention Type DRUG

Telmisartan 40 mg once daily for eight weeks

Telmisartan 80 mg

Telmisartan 80 mg once daily for eight weeks

Group Type EXPERIMENTAL

Telmisartan 80 mg

Intervention Type DRUG

Telmisartan 80 mg once daily for eight weeks

Amlodipine 2.5 mg

Amlodipine 2.5 mg once daily for eight weeks

Group Type EXPERIMENTAL

Amlodipine 2.5 mg

Intervention Type DRUG

Amlodipine 2.5 mg once daily for eight weeks

Amlodipine 5 mg

Amlodipine 5 mg once daily for eight weeks

Group Type EXPERIMENTAL

Amlodipine 5 mg

Intervention Type DRUG

amlodipine 5g once daily for eight weeks

Amlodipine 10 mg

Amlodipine 5 mg for two weeks and forced titrated to amlodipine 10 mg for six weeks once daily

Group Type ACTIVE_COMPARATOR

Amlodipine 5 mg

Intervention Type DRUG

amlodipine 5g once daily for two weeks

Amlodipine 10 mg

Intervention Type DRUG

Amlodipine 10 mg once daily for six weeks

Telmisartan 20 / Amlodipine 2.5

Telmisartan 20/ Amlodipine 2.5 mg once daily for eight weeks

Group Type EXPERIMENTAL

Telmisartan 20 mg

Intervention Type DRUG

Telmisartan 20 mg once daily for eight weeks

Amlodipine 2.5 mg

Intervention Type DRUG

Amlodipine 2.5 mg once daily for eight weeks

Telmisartan 20 / Amlodipine 5

Telmisartan 20 / Amlodipine 5 mg once daily for eight weeks

Group Type EXPERIMENTAL

Telmisartan 20 mg

Intervention Type DRUG

Telmisartan 20 mg once daily for eight weeks

Amlodipine 5 mg

Intervention Type DRUG

amlodipine 5mg once daily for eight weeks

Telmisartan 20 / Amlodipine 10

Telmisartan 20 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks

Group Type EXPERIMENTAL

Amlodipine 10 mg

Intervention Type DRUG

Amlodipine 10 mg once daily for six weeks

Telmisartan 20 mg

Intervention Type DRUG

Telmisartan 20 mg once daily for eight weeks

Amlodipine 5 mg

Intervention Type DRUG

Amlodipine 5 mg once daily for two weeks

Telmisartan 40 / Amlodipine 2.5

Telmisartan 40 / Amlodipine 2.5 for eight weeks

Group Type EXPERIMENTAL

Amlodipine 2.5 mg

Intervention Type DRUG

Amlodipine 2.5 mg once daily for eight weeks

Telmisartan 40 mg

Intervention Type DRUG

Telmisartan 40 mg once daily for eight weeks

Telmisartan 40 / Amlodipine 5

Telmisartan 40 / Amlodipine 5 for eight weeks

Group Type EXPERIMENTAL

Amlodipine 5 mg

Intervention Type DRUG

Amlodipine 5 mg once daily for eight weeks

Telmisartan 40 mg

Intervention Type DRUG

Telmisartan 40 mg once daily for eight weeks

Telmisartan 40 / Amlodipine 10

Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks

Group Type EXPERIMENTAL

Telmisartan 40 mg

Intervention Type DRUG

Telmisartan 40 mg once daily for eight weeks

Amlodipine 10 mg

Intervention Type DRUG

Amlodipine 10 mg once daily for six weeks

Amlodipine 5 mg

Intervention Type DRUG

Amlodipine 5 mg once daily for two weeks

Telmisartan 80 / Amlodipine 2.5

Telmisartan 80 / Amlodipine 2.5 for eight weeks

Group Type EXPERIMENTAL

Amlodipine 2.5 mg

Intervention Type DRUG

Amlodipine 2.5 mg once daily for eight weeks

Telmisartan 80 mg

Intervention Type DRUG

Telmisartan 80 mg once daily for eight weeks

Telmisartan 80 / Amlodipine 5

Telmisartan 80 / Amlodipine 5 mg for eight weeks

Group Type EXPERIMENTAL

Telmisartan 80 mg

Intervention Type DRUG

Telmisartan 80 mg once daily for eight weeks

Amlodipine 5 mg

Intervention Type DRUG

Amlodipine 5 mg once daily for eight weeks

Telmisartan 80 / Amlodipine 10

Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks

Group Type EXPERIMENTAL

Amlodipine 5 mg

Intervention Type DRUG

Amlodipine 5 mg once daily for two weeks

Telmisartan 80 mg

Intervention Type DRUG

Telmisartan 80 mg once daily for eight weeks

Amlodipine 10 mg

Intervention Type DRUG

Amlodipine 10 mg once daily for six weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amlodipine 5 mg

Amlodipine 5 mg once daily for two weeks

Intervention Type DRUG

Placebo

Placebo to Telmisartan and Amlodipine once daily for eight weeks

Intervention Type DRUG

Telmisartan 20 mg

Telmisartan 20 mg once daily for eight weeks

Intervention Type DRUG

Telmisartan 40 mg

Telmisartan 40 mg once daily for eight weeks

Intervention Type DRUG

Amlodipine 10 mg

Amlodipine 10 mg once daily for six weeks

Intervention Type DRUG

Telmisartan 20 mg

Telmisartan 20 mg once daily for eight weeks

Intervention Type DRUG

Telmisartan 80 mg

Telmisartan 80 mg once daily for eight weeks

Intervention Type DRUG

Amlodipine 10 mg

Amlodipine 10 mg once daily for six weeks

Intervention Type DRUG

Telmisartan 20 mg

Telmisartan 20 mg once daily for eight weeks

Intervention Type DRUG

Amlodipine 5 mg

Amlodipine 5 mg once daily for two weeks

Intervention Type DRUG

Amlodipine 5 mg

amlodipine 5g once daily for eight weeks

Intervention Type DRUG

Telmisartan 20 mg

Telmisartan 20 mg once daily for eight weeks

Intervention Type DRUG

Amlodipine 5 mg

Amlodipine 5 mg once daily for eight weeks

Intervention Type DRUG

Amlodipine 5 mg

amlodipine 5mg once daily for eight weeks

Intervention Type DRUG

Amlodipine 2.5 mg

Amlodipine 2.5 mg once daily for eight weeks

Intervention Type DRUG

Amlodipine 2.5 mg

Amlodipine 2.5 mg once daily for eight weeks

Intervention Type DRUG

Amlodipine 10 mg

Amlodipine 10 mg once daily for six weeks

Intervention Type DRUG

Amlodipine 2.5 mg

Amlodipine 2.5 mg once daily for eight weeks

Intervention Type DRUG

Telmisartan 80 mg

Telmisartan 80 mg once daily for eight weeks

Intervention Type DRUG

Telmisartan 80 mg

Telmisartan 80 mg once daily for eight weeks

Intervention Type DRUG

Amlodipine 5 mg

Amlodipine 5 mg once daily for two weeks

Intervention Type DRUG

Amlodipine 2.5 mg

Amlodipine 2.5 mg once daily for eight weeks

Intervention Type DRUG

Telmisartan 40 mg

Telmisartan 40 mg once daily for eight weeks

Intervention Type DRUG

Telmisartan 40 mg

Telmisartan 40 mg once daily for eight weeks

Intervention Type DRUG

Amlodipine 5 mg

amlodipine 5g once daily for two weeks

Intervention Type DRUG

Amlodipine 5 mg

Amlodipine 5 mg once daily for eight weeks

Intervention Type DRUG

Telmisartan 40 mg

Telmisartan 40 mg once daily for eight weeks

Intervention Type DRUG

Telmisartan 80 mg

Telmisartan 80 mg once daily for eight weeks

Intervention Type DRUG

Amlodipine 10 mg

Amlodipine 10 mg once daily for six weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

1. Patient is pregnant; breast-feeding; unwilling to use birth control during the study; has secondary hypertension; severe renal dysfunction; hepatic insufficiency; stroke within the last six months; myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past three months; unstable or uncontrolled diabetes for the past three months defined as a glucosylates hemoglobin (HbA1c) greater than ten percent ; history of angioedema or hypersensitivity related to either study drug.
2. Systolic Blood Pressure (SBP) is greater than or equal to 180 millimeters of mercury (mmHg), Diastolic Blood Pressure (DBP) is greater than or equal to 110 mmHg.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1235.1.457 Boehringer Ingelheim Investigational Site

Fairhope, Alabama, United States

Site Status

1235.1.368 Boehringer Ingelheim Investigational Site

Huntsville, Alabama, United States

Site Status

1235.1.389 Boehringer Ingelheim Investigational Site

Huntsville, Alabama, United States

Site Status

1235.1.411 Boehringer Ingelheim Investigational Site

Huntsville, Alabama, United States

Site Status

1235.1.429 Boehringer Ingelheim Investigational Site

Chandler, Arizona, United States

Site Status

1235.1.420 Boehringer Ingelheim Investigational Site

Tempe, Arizona, United States

Site Status

1235.1.391 Boehringer Ingelheim Investigational Site

Cudahy, California, United States

Site Status

1235.1.444 Boehringer Ingelheim Investigational Site

Encinitas, California, United States

Site Status

1235.1.445 Boehringer Ingelheim Investigational Site

Encino, California, United States

Site Status

1235.1.357 Boehringer Ingelheim Investigational Site

Long Beach, California, United States

Site Status

1235.1.465 Boehringer Ingelheim Investigational Site

Los Angeles, California, United States

Site Status

1235.1.441 Boehringer Ingelheim Investigational Site

Riverside, California, United States

Site Status

1235.1.409 Boehringer Ingelheim Investigational Site

Sacramento, California, United States

Site Status

1235.1.406 Boehringer Ingelheim Investigational Site

San Diego, California, United States

Site Status

1235.1.414 Boehringer Ingelheim Investigational Site

Santa Ana, California, United States

Site Status

1235.1.383 Boehringer Ingelheim Investigational Site

Spring Valley, California, United States

Site Status

1235.1.395 Boehringer Ingelheim Investigational Site

Tustin, California, United States

Site Status

1235.1.453 Boehringer Ingelheim Investigational Site

Milford, Connecticut, United States

Site Status

1235.1.394 Boehringer Ingelheim Investigational Site

Newark, Delaware, United States

Site Status

1235.1.354 Boehringer Ingelheim Investigational Site

Cooper City, Florida, United States

Site Status

1235.1.451 Boehringer Ingelheim Investigational Site

DeLand, Florida, United States

Site Status

1235.1.372 Boehringer Ingelheim Investigational Site

Fort Lauderdale, Florida, United States

Site Status

1235.1.396 Boehringer Ingelheim Investigational Site

Fort Lauderdale, Florida, United States

Site Status

1235.1.390 Boehringer Ingelheim Investigational Site

Hialeah, Florida, United States

Site Status

1235.1.430 Boehringer Ingelheim Investigational Site

Kissimmee, Florida, United States

Site Status

1235.1.351 Boehringer Ingelheim Investigational Site

Melbourne, Florida, United States

Site Status

1235.1.398 Boehringer Ingelheim Investigational Site

Melbourne, Florida, United States

Site Status

1235.1.405 Boehringer Ingelheim Investigational Site

Mirimar, Florida, United States

Site Status

1235.1.352 Boehringer Ingelheim Investigational Site

Pembroke Pines, Florida, United States

Site Status

1235.1.369 Boehringer Ingelheim Investigational Site

Pembroke Pines, Florida, United States

Site Status

1235.1.397 Boehringer Ingelheim Investigational Site

Pembroke Pines, Florida, United States

Site Status

1235.1.449 Boehringer Ingelheim Investigational Site

Pensacola, Florida, United States

Site Status

1235.1.355 Boehringer Ingelheim Investigational Site

Rockledge, Florida, United States

Site Status

1235.1.407 Boehringer Ingelheim Investigational Site

Tampa, Florida, United States

Site Status

1235.1.380 Boehringer Ingelheim Investigational Site

Tucker, Georgia, United States

Site Status

1235.1.438 Boehringer Ingelheim Investigational Site

Gurnee, Illinois, United States

Site Status

1235.1.373 Boehringer Ingelheim Investigational Site

Evansville, Indiana, United States

Site Status

1235.1.375 Boehringer Ingelheim Investigational Site

Evansville, Indiana, United States

Site Status

1235.1.415 Boehringer Ingelheim Investigational Site

Indianapolis, Indiana, United States

Site Status

1235.1.412 Boehringer Ingelheim Investigational Site

South Bend, Indiana, United States

Site Status

1235.1.435 Boehringer Ingelheim Investigational Site

Arkansas City, Kansas, United States

Site Status

1235.1.379 Boehringer Ingelheim Investigational Site

Lenexa, Kansas, United States

Site Status

1235.1.421 Boehringer Ingelheim Investigational Site

Newtown, Kansas, United States

Site Status

1235.1.356 Boehringer Ingelheim Investigational Site

Wichita, Kansas, United States

Site Status

1235.1.423 Boehringer Ingelheim Investigational Site

Louisville, Kentucky, United States

Site Status

1235.1.387 Boehringer Ingelheim Investigational Site

North Dartmouth, Massachusetts, United States

Site Status

1235.1.424 Boehringer Ingelheim Investigational Site

Bay City, Michigan, United States

Site Status

1235.1.385 Boehringer Ingelheim Investigational Site

Florissant, Missouri, United States

Site Status

1235.1.452 Boehringer Ingelheim Investigational Site

Florissant, Missouri, United States

Site Status

1235.1.365 Boehringer Ingelheim Investigational Site

Kansas City, Missouri, United States

Site Status

1235.1.431 Boehringer Ingelheim Investigational Site

Kansas City, Missouri, United States

Site Status

1235.1.454 Boehringer Ingelheim Investigational Site

Henderson, Nevada, United States

Site Status

1235.1.426 Boehringer Ingelheim Investigational Site

Cherry Hill, New Jersey, United States

Site Status

1235.1.434 Boehringer Ingelheim Investigational Site

Stratford, New Jersey, United States

Site Status

1235.1.366 Boehringer Ingelheim Investigational Site

East Syracuse, New York, United States

Site Status

1235.1.377 Boehringer Ingelheim Investigational Site

Northport, New York, United States

Site Status

1235.1.427 Boehringer Ingelheim Investigational Site

Rochester, New York, United States

Site Status

1235.1.381 Boehringer Ingelheim Investigational Site

Williamsville, New York, United States

Site Status

1235.1.410 Boehringer Ingelheim Investigational Site

Burlington, North Carolina, United States

Site Status

1235.1.400 Boehringer Ingelheim Investigational Site

Charlotte, North Carolina, United States

Site Status

1235.1.422 Boehringer Ingelheim Investigational Site

Greenboro, North Carolina, United States

Site Status

1235.1.403 Boehringer Ingelheim Investigational Site

Lenior, North Carolina, United States

Site Status

1235.1.376 Boehringer Ingelheim Investigational Site

Raleigh, North Carolina, United States

Site Status

1235.1.392 Boehringer Ingelheim Investigational Site

Raleigh, North Carolina, United States

Site Status

1235.1.384 Boehringer Ingelheim Investigational Site

Winston-Salem, North Carolina, United States

Site Status

1235.1.458 Boehringer Ingelheim Investigational Site

Winston-Salem, North Carolina, United States

Site Status

1235.1.374 Boehringer Ingelheim Investigational Site

Columbus, Ohio, United States

Site Status

1235.1.446 Boehringer Ingelheim Investigational Site

Columbus, Ohio, United States

Site Status

1235.1.413 Boehringer Ingelheim Investigational Site

Marion, Ohio, United States

Site Status

1235.1.359 Boehringer Ingelheim Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

1235.1.361 Boehringer Ingelheim Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

1235.1.436 Boehringer Ingelheim Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

1235.1.448 Boehringer Ingelheim Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

1235.1.386 Boehringer Ingelheim Investigational Site

Tulsa, Oklahoma, United States

Site Status

1235.1.439 Boehringer Ingelheim Investigational Site

Portland, Oregon, United States

Site Status

1235.1.440 Boehringer Ingelheim Investigational Site

Portland, Oregon, United States

Site Status

1235.1.408 Boehringer Ingelheim Investigational Site

Erie, Pennsylvania, United States

Site Status

1235.1.404 Boehringer Ingelheim Investigational Site

Lansdale, Pennsylvania, United States

Site Status

1235.1.428 Boehringer Ingelheim Investigational Site

Penndel, Pennsylvania, United States

Site Status

1235.1.370 Boehringer Ingelheim Investigational Site

East Providence, Rhode Island, United States

Site Status

1235.1.433 Boehringer Ingelheim Investigational Site

Beaufort, South Carolina, United States

Site Status

1235.1.462 Boehringer Ingelheim Investigational Site

Union, South Carolina, United States

Site Status

1235.1.417 Boehringer Ingelheim Investigational Site

Cordova, Tennessee, United States

Site Status

1235.1.459 Boehringer Ingelheim Investigational Site

Jackson, Tennessee, United States

Site Status

1235.1.363 Boehringer Ingelheim Investigational Site

New Tazewell, Tennessee, United States

Site Status

1235.1.382 Boehringer Ingelheim Investigational Site

Selmer, Tennessee, United States

Site Status

1235.1.442 Boehringer Ingelheim Investigational Site

Austin, Texas, United States

Site Status

1235.1.399 Boehringer Ingelheim Investigational Site

Carrollton, Texas, United States

Site Status

1235.1.460 Boehringer Ingelheim Investigational Site

Dallas, Texas, United States

Site Status

1235.1.443 Boehringer Ingelheim Investigational Site

Georgetown, Texas, United States

Site Status

1235.1.416 Boehringer Ingelheim Investigational Site

Killeen, Texas, United States

Site Status

1235.1.402 Boehringer Ingelheim Investigational Site

Lake Jackson, Texas, United States

Site Status

1235.1.432 Boehringer Ingelheim Investigational Site

McKinney, Texas, United States

Site Status

1235.1.456 Boehringer Ingelheim Investigational Site

Odessa, Texas, United States

Site Status

1235.1.418 Boehringer Ingelheim Investigational Site

Plano, Texas, United States

Site Status

1235.1.455 Boehringer Ingelheim Investigational Site

Waco, Texas, United States

Site Status

1235.1.358 Boehringer Ingelheim Investigational Site

Salt Lake City, Utah, United States

Site Status

1235.1.464 Boehringer Ingelheim Investigational Site

Salt Lake City, Utah, United States

Site Status

1235.1.437 Boehringer Ingelheim Investigational Site

Burke, Virginia, United States

Site Status

1235.1.447 Boehringer Ingelheim Investigational Site

Fredericksburg, Virginia, United States

Site Status

1235.1.371 Boehringer Ingelheim Investigational Site

Tacoma, Washington, United States

Site Status

1235.1.001 Boehringer Ingelheim Investigational Site

BsAs, , Argentina

Site Status

1235.1.004 Boehringer Ingelheim Investigational Site

Buenos Aires, , Argentina

Site Status

1235.1.005 Boehringer Ingelheim Investigational Site

Buenos Aires, , Argentina

Site Status

1235.1.006 Boehringer Ingelheim Investigational Site

Buenos Aires, , Argentina

Site Status

1235.1.002 Boehringer Ingelheim Investigational Site

Carlos Paz, , Argentina

Site Status

1235.1.003 Boehringer Ingelheim Investigational Site

Córdoba, , Argentina

Site Status

1235.1.115 Universidade Federal do Pará

Belém, , Brazil

Site Status

1235.1.102 Liga de Hipertensão Arterial

Goiânia, , Brazil

Site Status

1235.1.101 Clínica Médica

Rio de Janeiro, , Brazil

Site Status

1235.1.103 Unidade de Hipertensão - ICHC -

São Paulo, , Brazil

Site Status

1235.1.109 Centro de Pesquisas do Hospital do Rim e Hipertensão

São Paulo, , Brazil

Site Status

1235.1.203

Col. Magdalena de Las Salinas, , Mexico

Site Status

1235.1.210 Consultorio Privado

Durango, Durango, , Mexico

Site Status

1235.1.202

Guadalajara, Jalisco, , Mexico

Site Status

1235.1.209 Boehringer Ingelheim Investigational Site

Guadalajara, Jalisco, , Mexico

Site Status

1235.1.204

Lomas de Guevara, Guadalajara, , Mexico

Site Status

1235.1.208 "Ignacio Chávez"

Mexico City, , Mexico

Site Status

1235.1.211 Obesidad Y Prevencion de Enfermedades

Mexico City, , Mexico

Site Status

1235.1.212 en Factores de riesgo cardiovascular

México, , Mexico

Site Status

1235.1.205 Fraccionamiento Industrias

San Luis Potosí City, , Mexico

Site Status

1235.1.207

Zapopan, Jalisco, , Mexico

Site Status

1235.1.314 Boehringer Ingelheim Investigational Site

Benoni, , South Africa

Site Status

1235.1.302 Boehringer Ingelheim Investigational Site

Boksburg, , South Africa

Site Status

1235.1.306 Boehringer Ingelheim Investigational Site

Cape Town, , South Africa

Site Status

1235.1.309 Boehringer Ingelheim Investigational Site

Cape Town, , South Africa

Site Status

1235.1.310 Boehringer Ingelheim Investigational Site

Cape Town, , South Africa

Site Status

1235.1.311 Boehringer Ingelheim Investigational Site

Cape Town, , South Africa

Site Status

1235.1.304 Boehringer Ingelheim Investigational Site

Durban, , South Africa

Site Status

1235.1.312 Boehringer Ingelheim Investigational Site

Johannesburg, , South Africa

Site Status

1235.1.313 Boehringer Ingelheim Investigational Site

Johannesburg, , South Africa

Site Status

1235.1.307 Boehringer Ingelheim Investigational Site

Krugersdorp, , South Africa

Site Status

1235.1.303 Boehringer Ingelheim Investigational Site

Lenasia, , South Africa

Site Status

1235.1.305 Boehringer Ingelheim Investigational Site

Lenasia, , South Africa

Site Status

1235.1.301 Boehringer Ingelheim Investigational Site

Pretoria, , South Africa

Site Status

1235.1.308 Boehringer Ingelheim Investigational Site

Pretoria, , South Africa

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Brazil Mexico South Africa

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2008-000874-19

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1235.1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension
NCT00257491 COMPLETED PHASE3
Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine
NCT01911780 COMPLETED PHASE3
Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM
NCT00274612 COMPLETED PHASE4
PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN
NCT00274599 COMPLETED PHASE4
Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension
NCT02177422 COMPLETED PHASE3
Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension
NCT00553267 COMPLETED PHASE3
Open Label Study Telmisartan and Amlodipine in Hypertension
NCT00614380 COMPLETED PHASE3
Filtered Trial for Telmisartan 40mg Non-responder
NCT00550953 COMPLETED PHASE3
Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)
NCT02175355 COMPLETED PHASE3
26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension
NCT00624052 COMPLETED PHASE3
Telmisartan 80mg Non-responder Trial
NCT01222520 COMPLETED PHASE3
Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients
NCT01108809 COMPLETED
Telmisartan+Amlodipine Fixed Dose Combination in Hypertension
NCT01204398 COMPLETED PHASE3
Micardis® in Patients With Essential Hypertension
NCT02187705 COMPLETED
Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension
NCT00860262 COMPLETED PHASE3
Efficacy and Safety of TELMINUVO to Stage 2 Hypertension
NCT01983735 UNKNOWN PHASE3
Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities
NCT00242814 COMPLETED PHASE4
Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of 40 mg Telmisartan/5 mg Amlodipine and 80 mg Telmisartan/5 mg Amlodipine in Healthy Male Volunteers
NCT02194309 COMPLETED PHASE1
An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy
NCT01103960 COMPLETED PHASE3
Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension
NCT00326768 COMPLETED PHASE3
Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension
NCT04518293 COMPLETED PHASE3
Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension
NCT00425373 COMPLETED PHASE2/PHASE3
Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension
NCT02183701 COMPLETED PHASE3
Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
NCT02620163 COMPLETED PHASE3
Add-on to Micamlo BP Trial
NCT01975246 COMPLETED PHASE3